The Tobacco Products Scientific Advisory Committee; Notice of Meeting, 9910-9911 [2014-03705]
Download as PDF
rmajette on DSK2TPTVN1PROD with NOTICES
9910
Federal Register / Vol. 79, No. 35 / Friday, February 21, 2014 / Notices
hear presentations on the research
programs of the Laboratory Hemostasis,
Division of Hematology, Office of Blood
Research and Review, Center for
Biologics Evaluation and Research,
FDA.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: On March 18, 2014, from
8:30 a.m. to approximately 4:30 p.m.,
the meeting is open to the public.
Interested persons may present data,
information, or views, orally or in
writing, on issues pending before the
committee. Written submissions may be
made to the contact person on or before
March 11, 2014. Oral presentations from
the public on March 18, 2014, will be
scheduled between approximately 1:30
p.m. and 2 p.m. On March 19, 2014,
from 9 a.m. to approximately 11 a.m.,
the meeting is open to the public. Oral
presentations from the public on March
19, 2014, will be scheduled between
approximately 10:30 a.m. and 11 a.m.
Those individuals interested in making
formal oral presentations should notify
the contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before March 3, 2014. Time allotted
for each presentation may be limited. If
the number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by March 4, 2014.
Closed Committee Deliberations: On
March 19, 2014, from approximately 11
a.m. to 11:30 a.m., the meeting will be
closed to permit discussion where
disclosure would constitute a clearly
unwarranted invasion of personal
privacy (5 U.S.C. 552b(c)(6)). The
committee will discuss the site visit
report of the intramural research
VerDate Mar<15>2010
14:09 Feb 20, 2014
Jkt 232001
programs and make recommendations
regarding personnel staffing decisions.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets. Seating for
this meeting may be limited, so the
public is encouraged to watch the free
Webcast if unable to attend. The
Webcast will be available at 8:30 a.m. on
March 18, 2014, and on March 19, 2014,
at 9 a.m. at the link provided.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Bryan Emery
at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: February 18, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–03703 Filed 2–20–14; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–0001]
The Tobacco Products Scientific
Advisory Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: The Tobacco
Products Scientific Advisory
Committee.
General Function of the Committee:
To provide advice and
recommendations to the Agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on April 16, 2014, from 8:30 a.m.
to 5 p.m.; on April 17, 2014, from 8:30
PO 00000
Frm 00037
Fmt 4703
Sfmt 4703
a.m. to 5 p.m.; and on April 18, 2014,
from 8:30 a.m. to 3 p.m.
Location: Center for Tobacco
Products, 9200 Corporate Blvd.,
Rockville, MD 20850, 1–877–287–1373.
Contact Person: Caryn Cohen, Center
for Tobacco Products, Food and Drug
Administration, 9200 Corporate Blvd.,
Rockville, MD 20850, 1–877–287–1373
(choose option 5), email: TPSAC@
fda.hhs.gov, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last-minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
Agenda: On April 16, 2014, the
committee will consider scientific
issues pertaining to dependence and
addiction, including the development of
addiction, measurement of dependence
and addiction, and concepts concerning
the assessment of addiction in the
review of product submissions.
On April 17, 2014, the committee will
receive information on population
modeling in the assessment of tobacco
product applications and discuss the
ways modeling can inform decisions
critical to population health.
On April 18, 2014, the committee will
discuss possible approaches for
evaluating information on the risks and
potential benefits of a proposed
modified risk tobacco product to the
health of individual tobacco users and
to the population as a whole.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
E:\FR\FM\21FEN1.SGM
21FEN1
Federal Register / Vol. 79, No. 35 / Friday, February 21, 2014 / Notices
submissions may be made to the contact
person on or before April 2, 2014. Oral
presentations from the public will be
scheduled between approximately 1
p.m. and 1:30 p.m. on April 16; between
approximately 1 p.m. and 1:30 p.m. on
April 17; and between approximately
11:30 a.m. and 12 p.m. on April 18.
Those individuals interested in making
formal oral presentations should notify
the contact person and submit a brief
statement of the general nature of the
evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before March 25, 2014. Time allotted
for each presentation may be limited. If
the number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by March 24, 2014.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Caryn Cohen
at least 7 days in advance of the
meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
rmajette on DSK2TPTVN1PROD with NOTICES
Dated: February 18, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–03705 Filed 2–20–14; 8:45 am]
BILLING CODE 4160–01–P
VerDate Mar<15>2010
14:09 Feb 20, 2014
Jkt 232001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2014–N–0001]
Endocrinologic and Metabolic Drugs
Advisory Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Endocrinologic
and Metabolic Drugs Advisory
Committee.
General Function of the Committee:
To provide advice and
recommendations to the Agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on April 1, 2014, from 8 a.m. to 5
p.m.
Location: The Marriott Inn and
Conference Center, University of
Maryland University College (UMUC),
Potomac Ballroom, 3501 University
Blvd. East, Hyattsville, MD 20783. The
conference center’s telephone number is
301–985–7300.
Contact Person: Karen AbrahamBurrell, Center for Drug Evaluation and
Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 31, Rm. 2417, Silver Spring,
MD 20993–0002, 301–796–9001, FAX:
301–847–8533, email: EMDAC@
fda.hhs.gov, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s Web site at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before coming to the
meeting.
Agenda: The committee will discuss
new drug application (NDA) 22–472,
proposed trade name AFREZZA
(TECHNOSPHERE Insulin Inhalation
System), 3 unit and 6 unit cartridges for
oral inhalation, manufactured by
MannKind Corporation. The proposed
indication (use) for this application is to
improve glycemic control in adult
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
9911
patients with type 1 or type 2 diabetes
mellitus.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its Web site prior to the
meeting, the background material will
be made publicly available at the
location of the advisory committee
meeting, and the background material
will be posted on FDA’s Web site after
the meeting. Background material is
available at https://www.fda.gov/
AdvisoryCommittees/Calendar/
default.htm. Scroll down to the
appropriate advisory committee meeting
link.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person on or before March 18, 2014.
Oral presentations from the public will
be scheduled between approximately 1
p.m. and 2 p.m. Those individuals
interested in making formal oral
presentations should notify the contact
person and submit a brief statement of
the general nature of the evidence or
arguments they wish to present, the
names and addresses of proposed
participants, and an indication of the
approximate time requested to make
their presentation on or before March
10, 2014. Time allotted for each
presentation may be limited. If the
number of registrants requesting to
speak is greater than can be reasonably
accommodated during the scheduled
open public hearing session, FDA may
conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by March 11, 2014.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact Karen
Abraham-Burrell at least 7 days in
advance of the meeting.
FDA is committed to the orderly
conduct of its advisory committee
meetings. Please visit our Web site at
https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/
ucm111462.htm for procedures on
public conduct during advisory
committee meetings.
E:\FR\FM\21FEN1.SGM
21FEN1
Agencies
[Federal Register Volume 79, Number 35 (Friday, February 21, 2014)]
[Notices]
[Pages 9910-9911]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-03705]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2014-N-0001]
The Tobacco Products Scientific Advisory Committee; Notice of
Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: The Tobacco Products Scientific Advisory
Committee.
General Function of the Committee: To provide advice and
recommendations to the Agency on FDA's regulatory issues.
Date and Time: The meeting will be held on April 16, 2014, from
8:30 a.m. to 5 p.m.; on April 17, 2014, from 8:30 a.m. to 5 p.m.; and
on April 18, 2014, from 8:30 a.m. to 3 p.m.
Location: Center for Tobacco Products, 9200 Corporate Blvd.,
Rockville, MD 20850, 1-877-287-1373.
Contact Person: Caryn Cohen, Center for Tobacco Products, Food and
Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 1-877-
287-1373 (choose option 5), email: TPSAC@fda.hhs.gov, or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the
Washington, DC area). A notice in the Federal Register about last-
minute modifications that impact a previously announced advisory
committee meeting cannot always be published quickly enough to provide
timely notice. Therefore, you should always check the Agency's Web site
at https://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to
the appropriate advisory committee meeting link, or call the advisory
committee information line to learn about possible modifications before
coming to the meeting.
Agenda: On April 16, 2014, the committee will consider scientific
issues pertaining to dependence and addiction, including the
development of addiction, measurement of dependence and addiction, and
concepts concerning the assessment of addiction in the review of
product submissions.
On April 17, 2014, the committee will receive information on
population modeling in the assessment of tobacco product applications
and discuss the ways modeling can inform decisions critical to
population health.
On April 18, 2014, the committee will discuss possible approaches
for evaluating information on the risks and potential benefits of a
proposed modified risk tobacco product to the health of individual
tobacco users and to the population as a whole.
FDA intends to make background material available to the public no
later than 2 business days before the meeting. If FDA is unable to post
the background material on its Web site prior to the meeting, the
background material will be made publicly available at the location of
the advisory committee meeting, and the background material will be
posted on FDA's Web site after the meeting. Background material is
available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting
link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written
[[Page 9911]]
submissions may be made to the contact person on or before April 2,
2014. Oral presentations from the public will be scheduled between
approximately 1 p.m. and 1:30 p.m. on April 16; between approximately 1
p.m. and 1:30 p.m. on April 17; and between approximately 11:30 a.m.
and 12 p.m. on April 18. Those individuals interested in making formal
oral presentations should notify the contact person and submit a brief
statement of the general nature of the evidence or arguments they wish
to present, the names and addresses of proposed participants, and an
indication of the approximate time requested to make their presentation
on or before March 25, 2014. Time allotted for each presentation may be
limited. If the number of registrants requesting to speak is greater
than can be reasonably accommodated during the scheduled open public
hearing session, FDA may conduct a lottery to determine the speakers
for the scheduled open public hearing session. The contact person will
notify interested persons regarding their request to speak by March 24,
2014.
Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to electrical
outlets.
FDA welcomes the attendance of the public at its advisory committee
meetings and will make every effort to accommodate persons with
physical disabilities or special needs. If you require special
accommodations due to a disability, please contact Caryn Cohen at least
7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory committee
meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures
on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: February 18, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-03705 Filed 2-20-14; 8:45 am]
BILLING CODE 4160-01-P